CLAIMS

1. A compound of formula (I):



I

wherein

R5 is selected from the group consisting of 3-pyridyl, 5-pyrimidinyl, -CONH-(C_1-C_4 alkyl), -NHCO-(C_1-C_4 alkyl), halogen, -SO_2NH_2, -NO_2, -CF_3 or thien-2-ylcarbonyl and -CO_2R where R can be hydrogen or C_1-C_4 alkyl; and

Ar is selected from the group consisting of 5-imidazolyl, 2-pyrrolyl optionally substituted by a C_1-C_4 alkyl radical, 2-furyl or 2-thiazolyl,

in the E or Z geometrical isomeric form or a mixture of the two geometrical isomeric forms.

2. The compound according to Claim 1, wherein R5 is a 3-pyridyl or -CONH-methyl or -NHCO-methyl.

3. The compound according to Claim 1 or 2, wherein Ar is a 5-imidazolyl or a 5-(4-methylimidazolyl) or a 2-pyrrolyl group.

4. The compound according to Claim 1, wherein it is selected from group of formulae consisting of:

1,3-dihydro-3-(imidazol-4-ylmethylene)-5-(pyrid-3-yl)-2H-indolin-2-one;

1,3-dihydro-3-(pyrrol-2-ylmethylene)-5-(pyrid-3-yl)-2H-indolin-2-one;

1,3-dihydro-3-(imidazol-4-ylmethylene)-5-(N-methylcarboxamido)-2H-indolin-2-one; and

1,3-dihydro-3-(imidazol-4-ylmethylene)-5-(acetylamino)-2H-indolin-2-one.

5. A process for preparing the compound according to Claim 1, comprising coupling a compound of formula (II):



II

wherein
R5 is selected from the group consisting of 3-pyridyl, 5-pyrimidinyl, -CONH-(C_1-C_4 alkyl), -NHCO-(C_1-C_4 alkyl), halogen, -SO_2NH_2, -NO_2, -CF_3 or thien-2-ylcarbonyl and -CO_2R where R can be hydrogen or C_1-C_4 alkyl,
with a compound of formula (III):



III

wherein Ar is selected from the group consisting of 5-imidazolyl, 2-pyrrolyl optionally substituted by a C_1-C_4 alkyl radical, 2-furyl or 2-thiazolyl.

6. The process according to Claim 5, wherein the reaction is carried out in the presence of piperidine and of ethanol at reflux.

7. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to Claim 1 in a pharmaceutically acceptable medium.

8. The method of treating cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound according to Claim 1.

9. The method of Claim 8 wherein the cancer is a primary or secondary tumor.

10. The method of Claim 8 wherein the treating arises from the inhibition of a cyclin-dependent kinase.

11. The method of Claim 9, wherein the treating arises from the inhibition of CDK-1.

12. The method of Claim 8 wherein the treating further comprises combining the treating with radiotherapy, antiangiogenic treatment, or another chemotherapeutic.